Article Figures & Data
Figures
- FIGURE 1.
Comparison of SUVmax for DTC patients harboring BRAFV600E mutation versus BRAF-WT. *P = 0.019.
- FIGURE 2.
Comparison of SUVmax for DTC and PDTC patients harboring BRAF mutation. ns = nonsignificant. P = 0.91.
- FIGURE 3.
Distribution of SUVmax for all DTC and PDTC lesions, all BRAF-positive vs. -negative lesions, and BRAF-WT DTC vs. BRAF-WT PDTC lesions. There is a difference in SUVmax distribution of BRAF-WT DTC and BRAF-WT PDTC, even though results are not significant.
- FIGURE 4.
18F-FDG PET/CT scans in metastatic thyroid cancer patients with and without BRAFV600E mutations. All PET images are scaled from 0.0 to 5.0 g/mL to allow for visual comparison of 18F-FDG uptake. PET scans were acquired in 2 steps (patients' arms raised for images of chest and arms down for images of neck) to improve image quality. (A) A 66-y-old woman harboring DTC BRAF-WT showing lung nodule (1.1 cm in diameter on CT) with low 18F-FDG uptake (arrows). (B) An 83-y-old woman harboring DTC BRAFV600E with multiple 18F-FDG–positive lesions with high uptake. (C) A 64-y-old man harboring PDTC BRAF-WT with multiple lung nodules (up to 1.5 cm in diameter on CT; arrows) with low/no 18F-FDG uptake. (D) A 75-y-old woman harboring PDTC BRAFV600E with multiple lung nodules showing high 18F-FDG uptake.
Tables
DTC PDTC Characteristic BRAFV600E BRAF-WT BRAFV600E BRAF-WT n PT genotype 24 (2)* 24 (2)* 5 29 Lesions† 57 44 12 48 Lesions per patient <5 13 16 3 17 5–10 1 2 0 6 >10 10 7 2 6 18F-FDG PET Positive 21 19 5 20 Negative 3 5 0 9 Age (y) Mean ± SD 68 ± 11‡ 64 ± 11‡ 72 ± 11§ 61 ± 13§ Sex Female 13 15 1 16 Male 11 9 4 13 TNM TX 4 3 1 0 T1/a/b 1/1/2 4/0/0 0/0/0 0/0/2 T2/a/b 2/0/0 5/0/0 1/0/0 7/0/0 T3/a/b 8/0/0 5/0/0 1/0/0 10/4/1 T4/a/b 2/3/1 3/1/3 0/2/0 0/2/3 NX/0 4/6 4/11 1/1 0/18 N1/a/b 6/3/5 3/3/3 1/0/2 3/4/4 MX/0/1 4/19/1 4/14/6 1/2/2 0/23/6 Radioiodine (GBq)∥ Median/minimum/maximum 5.8/3.7/30.5 7.4/2.6/32.7 2.7/1.1/4.4 7.4/1.9/24.5 TSH (mU/L)¶ Median/minimum/maximum 0.07/0.01/4.92 0.03/0.02/1.63 0.1/0.02/1.7 0.04/0.02/15.2 Thyroglobulin (ng/mL)# Median/minimum/maximum 6.9/0.2/1,930 360/0.3/37,000 46.9/2.2/670 270/1.7/1,4400 PET to D Mean ± SD 31 ± 41** 24 ± 36** 40 ± 51†† 11 ± 26†† ↵* No. of patients, with follicular variant of PTC in parentheses.
↵† Only 1 lesion per site per patient (Table 2) was analyzed.
↵‡ P = 0.24, Mann–Whitney U test.
↵§ P = 0.10, Mann–Whitney U test.
↵∥ All patients with DTC received radioiodine; amount of 131I missing in n = 26, n = 2 patients with PDTC did not receive radioiodine, n = 1 no data about radioiodine available, n = 8 amount of 131I missing.
↵¶ For n = 2 patients with PDTC, no data were available.
↵# For n = 4 patients with DTC and n = 3 patients with PDTC, no thyroglobulin data were available and n = 4 patients with DTC had thyroglobulin level below 0.3 ng/mL, but for all of these patients, progress was stated with CT. Difference of thyroglobulin values in WT DTC was significantly higher than in BRAFV600E group (P = 0.009).
↵** P = 0.59, Mann–Whitney U test.
↵†† P = 0.16, Mann–Whitney U test.
PET to D = time difference between PET and diagnosis verified by molecular pathology, given in months.
DTC PDTC Parameter Value BRAFV600E BRAF-WT BRAFV600E BRAF-WT SUVmax Median 6.3 4.7 6.4 9.4 Minimum 1.6 1.1 1.9 2.3 Maximum 51.2 30.1 30.0 47.0 CT size (cm) Mean ± SD 1.6 ± 0.7 2.0 ± 1.5 1.9 ± 1.3 2.8 ± 1.9 Median 1.3 1.7 1.5 2.2 Minimum 0.6 0.4 0.6 0.6 Maximum 3.8 7.8 4.5 8.0
